

Boehringer Ingelheim is Pleased to Invite You to Join Our Virtual Symposium & Live Q&A Session

12:00–13:30 SGT Sunday, November 22

Channel 3. Available on-demand until November 29.

Treatment Considerations for Advanced NSCLC: Now and in the Future

A faculty of experts will discuss first-line treatment decisions for advanced EGFR mutation-positive NSCLC and the potential efficacy of EGFR TKIs in patients with uncommon EGFR mutations. Emerging strategies for the treatment of NSCLC will also be addressed.

Welcome

Byoung Chul Cho, MD, PhD

Yonsei Cancer Center, Seoul, South Korea

Navigating First-Line Treatment Decisions for EGFRM+ NSCLC: Extrapolating from Asian Clinical Trial Experience

John Wen-Cheng Chang, MD

Chang Gung Memorial Hospital, Taoyuan City, Taiwan

Tackling Uncommon EGFR Mutations: Efficacy of EGFR TKIs in NSCLC

Hiroshi Tanaka, MD

Niigata Cancer Center Hospital, Niigata, Japan

KRAS-mutant NSCLC Treatment Advances on the Horizon

Byoung Chul Cho, MD, PhD

Yonsei Cancer Center, Seoul, South Korea

Closing

Byoung Chul Cho, MD, PhD

Yonsei Cancer Center, Seoul, South Korea

Live Q&A Session

13:00–13:30 SGT

